Prostate Cancer
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (MK-5684-003)
- Details
ClinicalTrials.gov ID:
NCT06136624
Diagnosis Type:
NA
USOR Number:
- Address
,
P: